sbur Become a Member
Menu

Sbur is a founders and builders only community. Entrepreneurs join because they need to have three burning questions answered.

Here are the three questions — and Sbur’s answers.

  1. “Tell me what I’m not seeing.”

    Trusted Peer Insight — candid, battle-tested perspectives from people who have been there.

  2. “Who do I need to know?”

    High-Value Connections — curated access to the right people, opportunities, capital, talent and expertise.

  3. “Help me make it happen.”

    Actionable Solutions — practical ideas, accountability and resources that turn challenges into results.

Apply to join

Membership by approval.

Upcoming Get-Togethers with Entrepreneurs and Investors

Raising From Angels in Today’s Market: A Founder Roundtable with Rob Hickey, Angel Investor

Hosted by Rob Hickey, Investor • Angel Investor

RSVP to see the addressBoston

Fundraising for an early-stage company looks different than it did even a year or two ago. How do angel investors see the market right now, what makes them say yes, and how do you find and approach the right ones? I’m hosting a small, off-the-record roundtable for early-stage founders to talk through exactly that. This is a candid conversation where you can bring your real questions and hear how angels actually think. What we’ll cover: * How angel investors are viewing the current investment environment, and what’s changed * Where to find angels who are a genuine fit for your stage and sector * How to approach them: warm intros, cold outreach, and what makes a first conversation go well * What angels look for beyond the pitch deck, including the technical team, architecture and ability to scale * Common mistakes founders make when raising an angel round About me: I’m an angel investor focused on early-stage AI startups. I currently serve on technical advisory boards and invest in companies including Zerve AI, Avesha, and number of others. Before that, I spent nearly eight years at DataRobot, most recently as EVP of Engineering, helping grow the team from about a dozen engineers to over three hundred. Earlier in my career I was on the founding engineering team at Arrowpoint Communications (acquired by Cisco) and led engineering at Azuki Systems (acquired by Ericsson), so I’ve seen fundraising and exits from the founder’s side of the table as well. Who should join: Founders of pre-seed and seed-stage companies who are raising now or planning to raise in the next 6–12 months. Seats are limited to keep the conversation small and useful. Looking forward to the conversation

Join/RSVP

Founder Roundtable on Building in Biotech & Medtech Today

Hosted by Ted Cho, Healthcare Venture • Pear VC

RSVP to see the addressBoston

I’d like to invite you to a small, candid roundtable for biotech and medtech founders, investors, and operators, co-hosted with Alex Goddard, Director at Otsuka BioVentures. I’m Ted Cho. I work in healthcare venture at Pear VC and am a pediatric emergency medicine fellow at Boston Children’s Hospital. My path has run through venture and research at Rock Health, digital health policy as a CMS Fellow, and AI policy advising for the State of Utah, alongside an MD and MBA from Georgetown. Across those roles, I’ve seen how much of a company’s fate is shaped by forces outside the lab: capital, policy, reimbursement, and partner fit. Alex brings 20+ years from nearly every side of the table. He has been a neuroscientist at Harvard and Stanford, worked in discovery at Novartis, run R&D at startups, and led external innovation at Takeda. He now invests in early-stage companies. With one of us at an independent venture firm and the other at a corporate fund, we hope to offer two complementary investor perspectives. Capital is flowing again, but unevenly. It is concentrating in larger, later-stage rounds and in companies with near-term data, while the bar for Seed and Series A keeps rising. In medtech, acquisitions and strategic partnerships are filling much of the gap. We want to talk about what that means for founders building now. Proposed topics: 1. Bridging science and fundable data: reaching proof-of-concept in CNS, immunology, and rare disease when investors want de-risked assets. 2. Translational risk in hard indications: how biomarker, endpoint, and IND-enabling strategies can change the financing conversation. 3. AI in discovery: where investors see real value versus hype. 4. Medtech’s path to market: evidence, reimbursement, and strategic acquirers as the main exit. 5. Policy and pricing: how drug pricing, regulation, and global competition shape what gets funded. 6. VC vs. corporate VC: return mandates versus strategic alignment, partner expertise versus signaling and independence, and how to build syndicates that get the best of both. This is a working conversation. We want to hear what’s working for you, where you’re stuck, and what you wish investors and pharma partners understood. The group will be kept small, and the discussion will be held under Chatham House Rule.

Join/RSVP

60+ Commercial Property Operators, One Fall Evening, & You

Hosted by Reneldy Senat, Founder • Idoleyes Interactive

RSVP to see the addressBoston

Come for the connections. Leave with new relationships, and a better sense of where property operations are heading next. Geoffrey AI is partnering with SBUR to bring the commercial real estate community together in downtown Boston for a relaxed, relationship-driven evening built around the people shaping the future of property operations. This is an opportunity to meet the people you may want to know before the next opportunity, operational challenge, or urgent need arises. This room is designed for property owners, asset managers, property-management leaders, operations professionals, service providers, technology companies, and industry partners from across the CRE community. No long conference agenda. Just the right people, useful conversations, and time to build relationships.

Join/RSVP